Last reviewed · How we verify
NCT06135545
Bupivacaine Liposome Serrate Anterior Plane Block vs Traditional Thoracic Paravertebral Block
NA trial testing Bupivacaine Liposome SAPB in Lung Cancer. Withdrawn.
2 October 2023
Quick facts
| Lead sponsor | Shiyou Wei |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Start date | 1 October 2023 |
| Primary completion | 2 October 2023 |
| Estimated completion | 3 October 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bupivacaine Liposome SAPB
- Traditional TPVB
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Shiyou Wei — full company profile →
Who can join
Adults 18 to 75, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, patients will receive bupivacaine liposome serratus anterior plane block or ropivacaine paraspinal block to manage postoperative pain. Follow-up visits will be conducted to investigate the patient's postoperative pain and recovery quality. The investigators hypothesize that the simple and safe serratus anterior plane block with a novel long-acting local anesthetic (bupivacaine liposome) has analgesic efficacy and recovery quality that is not inferior to the currently commonly used bupivacaine paraspinal block.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06135545
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Shiyou Wei trials
Trials by the same sponsor.
- NCT07332546 — EOIB for Pain After Laparoscopic Cholecystectomy · NA · not yet recruiting
- NCT07204106 — Efficacy Study of Dexmedetomidine Nasal Spray Combined With Propofol for Deep Sedation in ERCP · NA · completed
- NCT07187765 — Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy · NA · completed
- NCT07154979 — Oliceridine Dose for Tracheal Intubation Hemodynamic Elevation: Up-and-Down Trial · NA · completed
- NCT05631028 — 95% Effective Dose(ED95) of Remimazolam During Dexmedetomidine Pretreatment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06135545 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shiyou Wei
- Last refreshed: 9 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06135545.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing